Synergistic lethality in chronic myeloid leukemia – targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment

Chronic myeloid leukemia (CML) is effectively treated with tyrosine kinase inhibitors (TKIs), targeting the BCR::ABL1 oncoprotein. Still, resistance to therapy, relapse after treatment discontinuation, and side effects remain significant issues of long-term TKI treatment. Preliminary studies have sh...

Descripción completa

Detalles Bibliográficos
Autores principales: Häselbarth, Lukas, Gamali, Sara, Saul, Domenica, Krumbholz, Manuela, Böttcher-Loschinski, Romy, Böttcher, Martin, Zou, Deyu, Metzler, Markus, Karow, Axel, Mougiakakos, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680331/
https://www.ncbi.nlm.nih.gov/pubmed/38012567
http://dx.doi.org/10.1186/s12885-023-11623-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680331/
https://www.ncbi.nlm.nih.gov/pubmed/38012567
http://dx.doi.org/10.1186/s12885-023-11623-6

Ejemplares similares